Australia markets open in 16 minutes

Sanofi (SNYNF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
100.00-3.92 (-3.77%)
At close: 02:34PM EST
Full screen
Trade prices are not sourced from all markets
Previous close103.92
Open101.92
Bid0.00 x 0
Ask0.00 x 0
Day's range100.00 - 101.92
52-week range88.75 - 112.65
Volume1,213
Avg. volume18,437
Market cap125.254B
Beta (5Y monthly)0.48
PE ratio (TTM)17.99
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield3.86 (3.72%)
Ex-dividend date05 May 2021
1y target estN/A
All
News
  • GlobeNewswire

    Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis

    Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of targeting IL-4 and IL-13, central drivers of type 2 inflammation, to address itch and skin lesionsData confirm results from first Phase 3 trial, with 60% of Dupixent patients meeting the primary endpoint of itch reduction compared to 18% of

  • GlobeNewswire

    Sanofi: Information concerning the total number of voting rights and shares – December 2021

    Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,526,866,030 €Registered office : 54, rue La Boétie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under n

  • GlobeNewswire

    Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines

    Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines Collaborative efforts aim to accelerate drug discovery and improve clinical successAgreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selectionResearch will be focused on up to 15 novel small molecule candidates across oncology and immunologyExscientia will receive an upfront cash paymen